Navigation Links
FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD)
Date:3/26/2008

BOSTON, March 26 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced that it has entered into a licensing agreement with Massachusetts General Hospital (MGH) for the development and commercialization of agents for diagnosis and treatment of Alzheimer's disease (AD). The licensed technologies, which were co-developed by FluoroPharma and MGH scientists, target multiple biological processes associated with AD. Currently, there is no single diagnostic test that proves a person has AD. Development of new options for early detection and treatment of Alzheimer's has the potential to improve patient care and create new paths for AD management for the more than 5M Americans that suffer from dementia and other cognitive deficits as a result of AD.

"Our molecular imaging approach to AD includes multiple molecular compositions that target AD associated phenomena -- low acetylcholine and amyloid plaque formation. With some agents, it may be possible to improve brain function by inhibiting the breakdown of acetylcholine, and with others we may be able to prevent the formation of amyloid plaque by inhibiting protein misfolding. As PET imaging tracers, these agents also have potential applications in both diagnosis of the disease and monitoring of the therapy, by differentially accumulating in regions of the brain affected by the disease compared to normal brain tissue," explained Dr. David Elmaleh, FluoroPharma's Chairman and Scientific Founder.

"The technology has the potential to be highly effective due to the agents' enhanced accumulation in the brain," said Dr. Kundakovic, FluoroPharma's President. "As PET imaging agents, these compounds may provide valuable information in patients where early diagnostic and therapeutic information is likely to have the greatest benefit."

About FluoroPharma

FluoroPharma is a molecular imaging company engaged
'/>"/>

SOURCE FluoroPharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Honeywell Expands Aclar(R) Production for Pharmaceutical Industry
2. Murad Expands International Presence With Appointment of Danny Guez
3. Sigma-Aldrich Amends Credit Facility and Expands Commercial Paper Program
4. VIE Healthcare Expands Its Operations in the Midwest, and Obtains First Local Client
5. Eating Disorders Program at Lucile Packard Childrens Hospital Expands to Include Young Adults
6. Dollar Thrifty Automotive Group Expands Mobile Managed Services Contract with InfoLogix
7. Life Spine Expands Home Office Space, More Than Doubling Space Occupied
8. Millennium Expands IBD Franchise with Addition of New Development Candidate
9. inVentiv Clinical Expands Operations to Emerging Latin American Region
10. Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally
11. AlphaDetail, Inc. Expands Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Research debunks the ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor single people who pass their 40th birthday without ever tying the knot, s
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
Breaking Medicine News(10 mins):Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2
...rgery in obese patients, especially in laproscopic...y catheter and an // arterial line, says a study ... Morbid obesity is a condition that has a ge...ts in controlling the obesity. One of the mo...
...placing lost sensory hair cells in the inner ear m...mals, say a recent study// published in Nature Med... viral vector found in a developmental regulatory ...row as the differentiated non-sensory cells of the...
...e researchers at Harvard School of Public Health h...duce the risk of having multiple// sclerosis (MS) ...amin D supplement had a 40% less chance of develop...here is no cure for this disease but modern day tr...
... is possible to reduce eye infections like keratit... for longer hours, reports British Journal// of Op...e on contact lens wearers for daily wear or extend...earers for a 12-month hospital based study and had...
...alysis of medical records of liver cancer patients...ics are stand a three fold risk // of developing l... After taking other factors into account, such as ...hich is a known risk factor for liver cancer, may ...
... the 83rd General Session of the International Ass..., Japanese scientists have presented the results o...good for people suffering from bad breath. Or...had sugar-free more and natural form of yogurt for...
Other Medicine News:
(Date:12/4/2009)EMERYVILLE, Calif., Dec. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it will host an investor teleconference and webcast. Principal investigators will discuss the data present
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is prese
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6William Dwyer Named to PerfectServe Advisory Board 57496 1William Dwyer Named to PerfectServe Advisory Board 57496 2Photos 3A The Makers of LISTERINE 28R 29 and REACH 28R 29 TOTAL CARE Products Unveil a New Laugh Out Loud Book Benefiting the National Childrens Oral 57494 1Photos 3A The Makers of LISTERINE 28R 29 and REACH 28R 29 TOTAL CARE Products Unveil a New Laugh Out Loud Book Benefiting the National Childrens Oral 57494 2Photos 3A The Makers of LISTERINE 28R 29 and REACH 28R 29 TOTAL CARE Products Unveil a New Laugh Out Loud Book Benefiting the National Childrens Oral 57494 3Cyberonics to Present at Maxim Group Growth Conference 57492 1Cyberonics to Present at Maxim Group Growth Conference 57492 2
... Reported Safety & Tolerability Profile,in Sub...CHICAGO, June 25 /PRNewswire-FirstCall/ -- Phase I...of the American Diabetes,Association demonstrated ...dase-4 (DPP-4) in development by Bristol-Myers,Squ...), in,combination with metformin, exhibited a stat...
...-Funded Immune Globulin Study Uncovers Sample,Mani...PRNewswire-USNewswire/ -- An analysis,released tod...,study ruling out a link between autism and Rh imm...ained the mercury-based,preservative thimerosal. B...red manipulation of the study sample, so that,earl...
Other Medicine Technology:Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 2Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 3Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 4Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 5Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 6Genetics Journal Thimerosal/Autism Study the 'Best Science Drug,Company Money Can Buy' 2Genetics Journal Thimerosal/Autism Study the 'Best Science Drug,Company Money Can Buy' 3
QuikCoag CaCl2
QuikCoag Control 2
..., compact design. Using optical light scatter for ...YN 3200 meets the needs of today's laboratory. The...-part differential analysis, automated sample hand...y. The system combines proven Multi-Angle Polarize...
Perclose A-T Suture-Mediated Closure
Medicine Products: